FDA approves betrixapan for extended DVT/PE prophylaxis
www.pulmccm.org
The US Food and Drug Administration (FDA) approved betrixaban (Bevyxxa), a new oral anticoagulant for prevention of venous thromboembolism (VTE) in hospitalized medical patients with risk factors for DVT/PE. With betrixaban, manufacturer Portola will seek to expand a tiny market niche it could immediately dominate: prophylaxis of DVT/PE extending for about a month after hospital discharge into the outpatient setting. Betrixaban is the only oral drug approved for this indication. Its competition, subcutaneously injected enoxaparin, is rarely used after hospital discharge except in the highest-risk patients. The FDA approved betrixaban with a fast-track designation and priority review, based on the
FDA approves betrixapan for extended DVT/PE prophylaxis
FDA approves betrixapan for extended DVT/PE…
FDA approves betrixapan for extended DVT/PE prophylaxis
The US Food and Drug Administration (FDA) approved betrixaban (Bevyxxa), a new oral anticoagulant for prevention of venous thromboembolism (VTE) in hospitalized medical patients with risk factors for DVT/PE. With betrixaban, manufacturer Portola will seek to expand a tiny market niche it could immediately dominate: prophylaxis of DVT/PE extending for about a month after hospital discharge into the outpatient setting. Betrixaban is the only oral drug approved for this indication. Its competition, subcutaneously injected enoxaparin, is rarely used after hospital discharge except in the highest-risk patients. The FDA approved betrixaban with a fast-track designation and priority review, based on the